Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
AstraZeneca
Colorcon

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR BIPERIDEN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Biperiden Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00148590 ↗ Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia Terminated Stanley Medical Research Institute Phase 3 2005-11-01 The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia. Psychopathological changes were assessed with the Positive and Negative Syndrome Scale (PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function were measured at baseline and week 6, and 24 by the California Verbal Learning Test, Benton Learning Test, Digit Span Forward and Backward Test, Continuous Performance Test, Stroop Test, Trail-Making Test, Verbal Fluency Test, and Wisconsin Card Sorting Test.
NCT00148590 ↗ Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia Terminated M. Schaefer, MD Phase 3 2005-11-01 The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia. Psychopathological changes were assessed with the Positive and Negative Syndrome Scale (PANSS) at baseline and after 2, 4, 6, 12, and 24 weeks. Cognitive function were measured at baseline and week 6, and 24 by the California Verbal Learning Test, Benton Learning Test, Digit Span Forward and Backward Test, Continuous Performance Test, Stroop Test, Trail-Making Test, Verbal Fluency Test, and Wisconsin Card Sorting Test.
NCT00148616 ↗ Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia Terminated Stanley Medical Research Institute Phase 3 2004-04-01 The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.
NCT00148616 ↗ Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia Terminated M. Schaefer, MD Phase 3 2004-04-01 The purpose of this study is to evaluate the efficacy and safety of 24 weeks memantine add-on treatment to risperidone for the treatment of negative symptomatology and cognitive impairment in patients with chronic schizophrenia.
NCT00495092 ↗ Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed Hospital Universitari Vall d'Hebron Research Institute Phase 2/Phase 3 2005-01-01 The aim of this study is to assess the efficacy of caffeine compared to placebo in detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also studied. 108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) or caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 6 months. Primary efficacy outcomes will be 1) patient comfort assessed with abstinence symptomatology, craving for cocaine and mental status during detoxifying period, 2) study retention and 3) cocaine use. Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.
NCT00495183 ↗ Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status Hospital Universitari Vall d'Hebron Research Institute Phase 4 2009-01-01 The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied. Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 10 days in an in-hospital setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Biperiden Hydrochloride

Condition Name

Condition Name for Biperiden Hydrochloride
Intervention Trials
Schizophrenia 4
Cocaine Dependence 2
Epilepsy, Post-Traumatic 1
Anxiety Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Biperiden Hydrochloride
Intervention Trials
Schizophrenia 5
Cocaine-Related Disorders 3
Cognitive Dysfunction 2
Wounds and Injuries 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Biperiden Hydrochloride

Trials by Country

Trials by Country for Biperiden Hydrochloride
Location Trials
Germany 3
Brazil 3
Taiwan 2
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Biperiden Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Biperiden Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Biperiden Hydrochloride
Clinical Trial Phase Trials
Terminated 3
Completed 3
Unknown status 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Biperiden Hydrochloride

Sponsor Name

Sponsor Name for Biperiden Hydrochloride
Sponsor Trials
Stanley Medical Research Institute 2
M. Schaefer, MD 2
Hospital Universitari Vall d'Hebron Research Institute 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Biperiden Hydrochloride
Sponsor Trials
Other 17
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Johnson and Johnson
Baxter
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.